MEDSIR, a Spain-based international company specialised in the strategic design of clinical trials, announced on Thursday that it has named Jyoti Mundra, PhD as its new chief business officer.
In the new role, Dr Mundra is to provide support in expediting the company's growth while improving its presence and business in North America. She will be heading a global business and marketing team to provide clinical solutions to biopharma companies and build a network with hospitals and institutions.
Dr Mundra has served at various full service CRO's, supporting biopharma companies to advance their drug pipeline. She has held the position of a director of Business Development at Sinclair Research. She also served in similar roles at Champions Oncology and Covance.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax